Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07806110 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer

Name: Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer — clinical trial record (NCT07806110)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorThe First Hospital of Jilin University

Started2026-07-30

View on ClinicalTrials.gov ↗

The First Hospital of Jilin University

86 trials monitored

See 2 trials at risk

Pancreatic Cancer

1,634 trials monitored

See 90 trials at risk

Based on the superior efficacy and safety profile of liposomal irinotecan over irinotecan in pancreatic cancer, as well as preliminary results from earlier studies evaluating nab-paclitaxel and gemcitabine (AG) combined with liposomal irinotecan, this study aims to further evaluate the efficacy and safety of liposomal irinotecan plus AG as neoadjuvant therapy in patients with resectable or borderline resectable pancreatic cancer (RPC/BRPC). The ultimate goal is to identify a more effective treatment regimen to prolong overall survival in this patient population.

Trial Details

NCT Number	NCT07806110
Lead Sponsor	The First Hospital of Jilin University
Conditions	Pancreas Ductal Adenocarcinoma
Enrollment	62 participants
Start Date	2026-07-30
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-08